姜黄素-青黛联合方案治疗活动性溃疡性结肠炎的真实世界经验:一项回顾性多中心队列研究
研究纳入五个三级学术中心2018至2022年的88例活动性溃疡性结肠炎患者,评估姜黄素-青黛联合方案诱导缓解的效果。第8至12周临床缓解率为46.5%,临床应答率为60.2%,粪便钙卫蛋白中位数从1000 μg/g降至75 μg/g,未发现明显安全性信号。
要点
- 姜黄素-青黛联合方案诱导活动性溃疡性结肠炎临床缓解率46.5%、临床应答率60.2%。
- 粪便钙卫蛋白中位数从基线1000 μg/g降至诱导结束75 μg/g(n=30对配对样本)。
- 生物制剂/小分子经治患者中临床缓解率39.5%、临床应答率58.1%。
核心结论
- 在该真实世界队列中,姜黄素-青黛联合方案有效诱导活动性溃疡性结肠炎患者的临床和生物标志物缓解,包括生物制剂/小分子经治患者。
研究设计与样本
- 回顾性多中心成人队列研究,来自五个三级学术中心,时间跨度为2018至2022年。
- 共纳入88例活动性溃疡性结肠炎患者,活动性定义为简易临床结肠炎活动指数(SCCAI)≥3分。
- 患者接受姜黄素-青黛联合方案诱导治疗,所有结局在维持稳定治疗的患者中分析。
主要发现
- 临床缓解(第8至12周SCCAI≤2且较基线下降≥3分)41例(46.5%),临床应答(SCCAI下降≥3分)53例(60.2%)。
- SCCAI中位数从7(IQR:5-9)降至2(IQR:1-3),p<0.0001。
- 基线使用皮质类固醇的26例患者中,7例实现无皮质类固醇缓解。
- 43例生物制剂/小分子经治患者中,临床缓解率39.5%,临床应答率58.1%。
- 粪便钙卫蛋白正常化17/29例,应答27/33例;中位数从基线1000 μg/g(IQR:392-2772)降至诱导结束75 μg/g(IQR:12-136)(n=30对配对样本),p<0.0001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Curcumin and QingDai (QD, Indigo) have been shown to be effective for treating active ulcerative colitis (UC). AIM: To evaluate the real-world experience with the Curcumin-QingDai (CurQD) herbal combination to induce remission in active UC. METHODS: A retrospec-tive multicentre adult cohort study from five tertiary academic centres (2018-2022). Active UC was defined as a Simple Clinical Colitis Activity Index (SCCAI) ≥ 3. Patients were induced by CurQD. The primary outcome was clinical remission at weeks 8-12, defined as SCCAI ≤2 and a decrease ≥3 points from baseline. Secondary outcomes were clinical response (SCCAI decrease ≥3 points), corticosteroid-free remission, faecal calprotectin (FC) response (reduction ≥50%), FC normalisation (FC ≤100 μg/g for patients with FC ≥300 μg/g at baseline), and safety. All outcomes were analysed for patients who were maintaining stable treatment. RESULTS: Eighty-eight patients were included; 50% were biologics/small molecules experienced, and 36.5% received ≥2 biologics/small molecules. Clinical remission was achieved in 41 (46.5%), and clinical response in 53 (60.2%). Median SCCAI decreased from 7 (IQR:5-9) to 2 (IQR:1-3); p < 0.0001. Of the 26 patients on corticosteroids at baseline, seven achieved corticosteroid-free remission. Among 43 biologics/small molecules experienced patients, clinical remission was achieved in 39.5% and clinical response in 58.1%. FC normalisation and response were achieved in 17/29 and 27/33, respectively. Median FC decreased from 1000 μg/g (IQR:392-2772) at baseline to 75 μg/g (IQR:12-136) at the end of inductions (n = 30 patients with paired samples); p < 0.0001. No overt safety signals emerged. CONCLUSION: In this real-world cohort, CurQD effectively induced clinical and biomarker remission in patients with active UC, including patients who were biologics/small molecules experienced.
引用
- Yanai H, Salomon N, Lahat A, et al. Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study. Aliment Pharmacol Ther. 2023. PMID: 37157131. doi:10.1111/apt.17538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。